Status:
UNKNOWN
Acute Sympotomatic Seizure Secondary to Autoimmune Encephalitis and Autoimmune-associated Epilepsy
Lead Sponsor:
Liu Yonghong
Collaborating Sponsors:
First Affiliated Hospital Xi'an Jiaotong University
Second Affiliated Hospital of Xi'an Jiaotong University
Conditions:
Autoimmune Encephalitis
Epilepsy
Eligibility:
All Genders
Brief Summary
Previously, scholars called the seizures secondary to autoimmune encephalitis（AE） "autoimmune related epilepsy", but the seizures secondary to AE are usually controlled after the improvement of enceph...
Eligibility Criteria
Inclusion
- Confirmed autoimmune encephalitis (2016,Lancet);
- Meet the classification criteria for epilepsy (2017,International League Against Epilepsy);
- Patients who still have seizures after taking ASM after the control of AE disease were included in the third part of the study;
- All patients volunteered and signed an informed consent form;
Exclusion
- Incomplete key clinical data;
- People with epilepsy or other intracranial diseases before diagnosis;
- There is no epileptic author during the onset of autoimmune encephalitis;
Key Trial Info
Start Date :
January 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT05422664
Start Date
January 1 2018
End Date
December 31 2025
Last Update
July 14 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
XijingH
Xi'an, Shaanxi, China, 710000